BFS
NNNN

Bare Financial Services’s Anbio Biotechnology NNNN Stock Holding History

Bare Financial Services’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206 Hold
15
– – ﹤0.01% 1772
2026
Q1 		$385 Buy
+15
New +$391 ﹤0.01% 1672

Other funds holding NNNN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.81B AUM 32.31% 1-Year Est. Return

Bare Financial Services's NNNN Position: Q2 2026 in Review

Bare Financial Services held its Anbio Biotechnology (NNNN) position steady in Q2 2026 at 15 shares worth $206. The position accounts for ﹤0.01% of the portfolio, ranked #1772.

Bare Financial Services first reported a position in NNNN in Q1 2026 and has held it in 2 quarters since. The position peaked at $385 in Q1 2026. 12 funds tracked by Wall St. Rank hold NNNN as of Q2 2026.

  • Bare Financial Services held 15 shares of Anbio Biotechnology worth $206 as of Q2 2026.
  • Bare Financial Services left its Anbio Biotechnology share count unchanged in Q2 2026.
  • Anbio Biotechnology made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1772 holding.
  • Bare Financial Services first reported a position in Anbio Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • Bare Financial Services's Anbio Biotechnology position peaked at $385 in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.